The table below shows Design Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$16.43M
-$16.79M
-$12.44M
-$17.42M
-$11.83M
-$3.70M
Capital expenditure
$0.00
$72.00K
$195.00K
$87.00K
$76.00K
$33.00K
Investing cash flow
-$7.59M
$7.87M
$20.62M
$19.73M
$414.00K
$23.03M
Dividends paid
-
-
-
-
DSGN operating cash flow (10-K history)
Design Therapeutics, Inc. reported operating cash flow of -$54.36M for fiscal year 2025. That is down 26.1% from -$43.10M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$8.67M (FY 2020) to -$54.36M. Figures come from the company's audited annual reports as filed with the SEC.